•
Jun 30, 2024

TELA Bio Q2 2024 Earnings Report

TELA Bio reported an 11% increase in revenue compared to the same period in 2023, driven by increased unit sales, offset by decreased average selling prices. The company is reiterating its full-year revenue guidance.

Key Takeaways

TELA Bio reported revenue of $16.1 million for the second quarter of 2024, an 11% increase compared to the same period in 2023. The company is reiterating its 2024 revenue target of $74.5 million to $76.5 million.

Revenue increased by 11% to $16.1 million compared to Q2 2023.

Gross profit was $11.1 million, representing 69% of revenue.

Operating expenses were $22.6 million.

Net loss was $12.6 million.

Total Revenue
$16.1M
Previous year: $14.5M
+11.0%
EPS
-$0.51
Previous year: -$0.46
+10.9%
Gross Profit
$11.1M
Previous year: $10.2M
+8.8%
Cash and Equivalents
$26.5M
Previous year: $65.3M
-59.4%
Free Cash Flow
-$11M
Previous year: -$11.4M
-3.7%
Total Assets
$60.2M
Previous year: $94.4M
-36.2%

TELA Bio

TELA Bio

Forward Guidance

TELA Bio is reiterating its 2024 revenue target of $74.5 million to $76.5 million.